Aspirin chemoprevention recommendations


Fam Pract Manag. 2004 Jun;11(6):18.

To the Editor:

I would like to recognize Dr. Phil Mohler’s effort to explain the challenging aspirin chemoprevention recommendation made by the U.S. Preventive Services Task Force (USPSTF). In “Weighing the Risks and Benefits of Clinical Interventions” [January 2004, page 53], Dr. Mohler states, “ … patients without known cardiovascular disease but with at least a five-year 3-percent risk for a CV event be treated with 81 mg of aspirin daily” and that the USPSTF “… gave this intervention its highest rating, an ‘A,’ meaning it is strongly recommended.” While the USPSTF did give its aspirin chemoprevention recommendation its highest rating, it was not explicitly recommending aspirin’s use, but rather recommending that “(C)linicians discuss [emphasis added] aspirin chemoprevention with adults who are at increased risk for coronary heart disease” and that these discussions “… should address both the potential benefits and harms of aspirin therapy.”1 It is also worth noting that the USPSTF found no study that demonstrated a decrease in all-cause mortality using aspirin as chemoprevention.1

To put it another way, the USPSTF does not appear to recommend aspirin for primary chemoprevention for coronary heart disease per se, but rather recommends a discussion of the incidence of cardiovascular disease and the risks and benefits of using aspirin to modify cardiovascular disease risk. It should also be noted that both Dr. Mohler and the USPSTF recommend that the discussion between the clinician and patient be based on estimating the patient’s risk of CAD, which can be done using the tools in the article. A worthwhile synopsis of the USPSTF’s approach to shared decision making was recently published, explaining how risk can be individualized to help come to an informed decision in line with a patient’s unique preferences.2


1. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136: 157-160.

2. Sheridan SL, Harris RP, Woolf SH. Shared Decision-Making Workgroup of the U.S. Preventive Services Task Force. Shared decision making about screening and chemoprevention: a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. January2004;261:56-66.


Send your comments to fpmedit@aafp.org. Submission of a letter will be construed as granting AAFP permission to publish the letter in any of its publications in any form. We cannot respond to all letters we receive. Those chosen for publication will be edited for length and style.


Copyright © 2004 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact fpmserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


May-Jun 2022

Access the latest issue
of FPM journal

Read the Issue

FPM E-Newsletter

Sign up to receive FPM's free, weekly e-newsletter, "Quick Tips & Insights."

Sign Up Now



Measuring What Matters in Primary Care: Implementing the Person-Centered Primary Care Measure

Learn how family physicians are using the person-centered primary care measure and get tips for how to implement it in your practice.

Improving Adult Immunization Rates Within Racial and Ethnic Minority Communities

Part one of this two-part supplement series highlights QI processes to reduce vaccine disparities, identifies recommended adult vaccines, and discusses their importance among racial and ethnic minority communities.